Triple therapy for corneal neovascularization: a case report.

PURPOSE: To investigate the effect of the combination of photodynamic therapy with verteporfin and subconjunctival bevacizumab and triamcinolone acetonide on corneal neovascularization secondary to corneal graft failure.

METHODS

A patient with extensive deep and superficial corneal neovascularization underwent same day triple therapy with subconjunctival bevacizumab (1.25 mg), subconjunctival triamcinolone acetonide (40 mg), and photodynamic therapy with verteporfin (fluence 50 J/cm², irradiance 300 mW/cm²).

RESULTS

A complete angiographic new vessel regression was obtained and was discernible starting 7 days after combination therapy. Three months after treatment, an initial new-vessel sprout was noted. Triple therapy was then repeated. No angiographic evidence of corneal neovascularization was detectable for the entire 6-month follow-up duration.

CONCLUSIONS

Triple therapy may offer a promising tool in the treatment of corneal neovascularization.